Last reviewed 2026-04-23 · How we verify

vehicle of LAS41007

Almirall, S.A. · Phase 3 active Small molecule

vehicle of LAS41007 is a PDE4 inhibitor Small molecule drug developed by Almirall, S.A.. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD).

LAS41007 is a small molecule inhibitor of the PDE4 enzyme.

LAS41007 is a small molecule inhibitor of the PDE4 enzyme. Used for Chronic obstructive pulmonary disease (COPD).

At a glance

Generic name	vehicle of LAS41007
Sponsor	Almirall, S.A.
Drug class	PDE4 inhibitor
Target	PDE4
Modality	Small molecule
Therapeutic area	Respiratory
Phase	Phase 3

Mechanism of action

PDE4 inhibition is thought to modulate inflammatory responses and potentially treat various conditions associated with inflammation.

Approved indications

Chronic obstructive pulmonary disease (COPD)

Common side effects

Nausea
Headache
Diarrhea

Key clinical trials

Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

vehicle of LAS41007 CI brief — competitive landscape report
vehicle of LAS41007 updates RSS · CI watch RSS
Almirall, S.A. portfolio CI

Frequently asked questions about vehicle of LAS41007

What is vehicle of LAS41007?

vehicle of LAS41007 is a PDE4 inhibitor drug developed by Almirall, S.A., indicated for Chronic obstructive pulmonary disease (COPD).

How does vehicle of LAS41007 work?

LAS41007 is a small molecule inhibitor of the PDE4 enzyme.

What is vehicle of LAS41007 used for?

vehicle of LAS41007 is indicated for Chronic obstructive pulmonary disease (COPD).

Who makes vehicle of LAS41007?

vehicle of LAS41007 is developed by Almirall, S.A. (see full Almirall, S.A. pipeline at /company/almirall-s-a).

What drug class is vehicle of LAS41007 in?

vehicle of LAS41007 belongs to the PDE4 inhibitor class. See all PDE4 inhibitor drugs at /class/pde4-inhibitor.

What development phase is vehicle of LAS41007 in?

vehicle of LAS41007 is in Phase 3.

What are the side effects of vehicle of LAS41007?

Common side effects of vehicle of LAS41007 include Nausea, Headache, Diarrhea.

What does vehicle of LAS41007 target?

vehicle of LAS41007 targets PDE4 and is a PDE4 inhibitor.

Drug class: All PDE4 inhibitor drugs
Target: All drugs targeting PDE4
Manufacturer: Almirall, S.A. — full pipeline
Therapeutic area: All drugs in Respiratory
Indication: Drugs for Chronic obstructive pulmonary disease (COPD)